Petros Pharmaceuticals 2021 Investor Presentation PTPI

Petros Pharmaceuticals presents its growth strategy for Stendra®, a patented erectile dysfunction treatment licensed from Vivus. The company achieved 106% quarterly revenue growth from H1 2020 to H1 2021 and outlines plans including a potential over-the-counter ED product and expansion in the projected $4.7B global ED market.